Individuals with undetected stable angina pectoris (SAP) as a consequence of undiagnosed coronary artery disease are at high risk of poor quality of life and a premature fatal event (for example, ...
In January 2006, the U.S. Food and Drug Administration (FDA) approved a new antianginal agent for the treatment of chronic stable angina, ranolazine (Ranexa™; CV Therapeutics, Inc.). The drug, ...
Add Yahoo as a preferred source to see more of our stories on Google. If angina pectoris – pain, pressure or tightness and shortness of breath – suddenly occurs even at rest, this can indicate an ...
The safety of fractional flow reserve (FFR)-based deferral of nonculprit lesions in patients varies by presentation, a pooled analysis of more than 8,000 patients confirms. Among those whose treatment ...
Angina pectoris, often shortened to angina, is chest pain or discomfort caused by reduced blood flow to the heart and most commonly—but not always—a symptom of coronary artery disease (CAD). The term ...
When a robust man suddenly drops dead and the newspapers report “heart failure,” the probability is that he died during an attack of angina pectoris. If he had gone to his doctor the day before, the ...
A drug used in the clinical treatment of angina symptoms also has an anti-inflammatory effect and reduces atherosclerotic plaques in blood vessels - thereby reducing the risk of heart attack or stroke ...
A drug used in the clinical treatment of angina symptoms also has an anti-inflammatory effect and reduces atherosclerotic plaques in blood vessels - thereby reducing the risk of heart attack or stroke ...
Most patients with coronary artery disease (CAD) and chronic stable angina will obtain complete relief of symptoms with percutaneous coronary intervention (PCI). However, some chronic angina patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results